SLC6A3 and Dyskinesia: Although the number of patients included in our sub-analysis was low and the results should be interpreted with caution, we emphasize an important recommendation [48,49] to consider DAT eligibility according to other clinical parameters, including five daily levodopa doses and lack of dyskinesia response to amantadine 100–400 mg/day, than PD duration.